CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.
Status:
Recruiting
Trial end date:
2024-02-06
Target enrollment:
Participant gender:
Summary
It has been recently reported that EATL type 1, but not refractory coeliac disease, strongly
expressed CD30 and might benefit from brentuximab vedotin. Since the safety profile of the
combination brentuximab vedotin and CHP is known and since the role of etoposide as part of
induction regimen is not demonstrated, the investigator will assess the efficacy and toxicity
of the combination brentuximab vedotin and CHP followed by HDT/ASCT, as frontline treatment
of EATL.